+45%

est. 2Y upside i

HealthcareSeries A

We build the AI companion for nurses, to create time for care.

Rank

#1857

Sector

HealthTech

Est. Liquidity

~6Y

Data Quality

Data: Medium

voize is a credible Series A HealthTech opportunity — $9.4M in revenue, Balderton backing, and a differentiated niche in EU nursing AI documentation are real positives — but the 26.6x revenue multiple bakes in aggressive growth that the available data does not yet confirm.

Last updated: May 13, 2026

Bull (20%)+180%

voize deploys its $50M Series A to capture 3–5% of the German and broader EU nursing market, scaling revenue from $9.4M to $30M+ within 2 years (~185% CAGR). Balderton drives a Series B at $600M–$700M, representing roughly 180% upside from the current $250M valuation.

Base (52%)+55%

Steady DACH expansion brings revenue to ~$18M by year 2 (~40% annual growth), and voize closes a Series B at $375M–$400M — approximately 55% upside on the current $250M valuation, though common-stock holders face meaningful dilution from the new round.

Bear (28%)-70%

German healthcare digitization stalls, enterprise sales cycles extend well beyond projections, and revenue plateaus near $12M; voize requires a bridge or down round that compresses valuation to $75M–$125M, wiping out roughly 70% of common-stock value at this entry point.

Est. time to liquidity~6.0 years

Preference Stack Risk

high

Funding Intensity

24%

$59.5M in total liquidation preferences must be cleared before common stockholders participate in proceeds, representing 23.8% of the $250M current valuation.

Dilution Risk

high

As a freshly closed Series A company requiring multiple future rounds to reach exit scale, equity-stake dilution of 30–50%+ is expected before any liquidity event.

Secondary Liquidity

none

No secondary market exists for voize shares at this stage; the equity is fully illiquid until a future M&A transaction or IPO.

Customer Support — 2 roles

Business Development — 1 role

Operations — 1 role

Partnership — 1 role

View all 23 open roles at voize →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on voize's data — designed to show you've done your homework.

  • 1

    “What is your current ARR and YoY growth rate, and how does the $50M Series A change your 24-month revenue target — specifically, what ARR milestone triggers the Series B?”

  • 2

    “What is your net revenue retention and average contract value across customers like KORIAN and Caritas Stuttgart — how sticky is the product once deployed at a nursing home?”

  • 3

    “What is the current 409A fair-market value for common stock, and what is the option strike price relative to the $250M preferred-round valuation?”

Community

Valuation Sentiment

Our model estimates +45% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.